IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+2.37%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$360M
AUM Growth
+$360M
(+9.4%)
Cap. Flow
+$8.2M
Cap. Flow
% of AUM
2.28%
Top 10 Holdings %
Top 10 Hldgs %
35.72%
Holding
175
New
41
Increased
20
Reduced
27
Closed
26
Top Buys
| 1 |
Milestone Pharmaceuticals
MIST
|
$12.8M |
| 2 |
TCON
TRACON Pharmaceuticals, Inc. Common Stock
TCON
|
$11.2M |
| 3 |
89bio
ETNB
|
$8.73M |
| 4 |
IMAB
I-MAB
IMAB
|
$7.05M |
| 5 |
Immatics
IMTX
|
$6.77M |
Top Sells
| 1 |
Achieve Life Sciences
ACHV
|
$28.3M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$15.7M |
| 3 |
Adicet Bio
ACET
|
$14M |
| 4 |
Kura Oncology
KURA
|
$14M |
| 5 |
BioXcel Therapeutics
BTAI
|
$11.5M |
Sector Composition
| 1 | Healthcare | 96.72% |
| 2 | Industrials | 0% |
| 3 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Mustang Bio
MBIO
$11.2M
| $2.54M | 0.18% |
806,475
+450,000
| +126% | +$1.42M |
|
52
Xenon Pharmaceuticals
XENE
$3.01B
| $2.47M | 0.18% |
223,173
-75,000
| -25% | -$830K |
|
|
53
Achieve Life Sciences
ACHV
$147M
| $2.38M | 0.17% |
284,151
-3,374,386
| -92% | -$28.3M |
|
54
CASI Pharmaceuticals
CASI
$36.1M
| $2.36M | 0.17% |
1,539,910
+500,000
| +48% | +$765K |
|
55
Acadia Pharmaceuticals
ACAD
$4.3B
| $2.31M | 0.17% |
56,008
+10,000
| +22% | +$412K |
|
|
BLUE
56
DELISTED
bluebird bio
BLUE
| $2.17M | 0.16% |
40,281
-64,593
| -62% | -$3.48M |
|
|
PSTX
57
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $2.02M | 0.15% |
+228,000
| New | +$2.02M |
|
58
Quince Therapeutics
QNCX
$84.9M
| $2M | 0.14% |
+40,000
| New | +$2M |
|
|
OTIC
59
DELISTED
Otonomy, Inc.
OTIC
| $1.76M | 0.13% |
434,786
-632,485
| -59% | -$2.56M |
|
60
NextCure
NXTC
$13.3M
| $1.76M | 0.13% |
+200,000
| New | +$1.76M |
|
61
DiaMedica Therapeutics
DMAC
$268M
| $1.76M | 0.13% |
+415,000
| New | +$1.76M |
|
62
Verastem
VSTM
$568M
| $1.71M | 0.12% |
1,413,327
-500,000
| -26% | -$605K |
|
|
APTX
63
DELISTED
Aptinyx Inc. Common Stock
APTX
| $1.68M | 0.12% |
495,490
-95,510
| -16% | -$323K |
|
64
Rigel Pharmaceuticals
RIGL
$697M
| $1.67M | 0.12% |
695,529
-985,000
| -59% | -$2.36M |
|
|
TECX
65
Tectonic Therapeutic, Inc. Common Stock
TECX
$318M
| $1.63M | 0.12% |
+125,000
| New | +$1.63M |
|
66
Solid Biosciences
SLDB
$430M
| $1.6M | 0.12% |
788,008
| – | – |
|
|
ICAD
67
DELISTED
iCAD Inc
ICAD
| $1.6M | 0.12% |
181,337
-130,931
| -42% | -$1.15M |
|
68
Altimmune
ALT
$326M
| $1.5M | 0.11% |
113,768
-51,232
| -31% | -$676K |
|
69
Cytokinetics
CYTK
$5.79B
| $1.19M | 0.09% |
+55,000
| New | +$1.19M |
|
70
Delcath Systems
DCTH
$384M
| $1.09M | 0.08% |
94,000
| – | – |
|
71
Biogen
BIIB
$20.7B
| $852K | 0.06% |
3,000
+2,205
| +277% | +$626K |
|
|
SIOX
72
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $820K | 0.06% |
177,684
-11,200
| -6% | -$51.7K |
|
73
Vaxcyte
PCVX
$4.11B
| $796K | 0.06% |
16,110
-123,703
| -88% | -$6.11M |
|
74
Crinetics Pharmaceuticals
CRNX
$3.21B
| $784K | 0.06% |
+50,000
| New | +$784K |
|
75
AnaptysBio
ANAB
$602M
| $738K | 0.05% |
50,000
+45,419
| +991% | +$670K |
|